Just another guy with a day job and an obsession with stocks... goal is to find stocks that are TURNING THE CORNER, where a good story and an interesting stock chart result in a high probability of large % gains. These stocks can typically achieve such momentum that alpha is generated in both bear and bull markets. I generally stick to under the radar growth and turnaround ideas, some of which may give investors time to establish a position. Ideally, I prefer to hold these companies medium to long term, but am not averse to selling shares if they become extremely overvalued or my thesis changes.
I continue to refine my strategy and risk management through sharing my ideas publicly and managing a large private account. I rely on strong fundamental analysis, high conviction positions (mainly long/a few shorts are possible when they meet my criteria), and preplanned allocations (% of portfolio) to avoid overconfidence, as the market eventually humbles us all from time to time. I also have a smattering of macro calls and contrarian positions as well. I have several screens that I use to come up with under the radar ideas, focusing on mainly growth and turnaround stocks with multiple upcoming catalysts.
Best Call: Celldex (established position between $2 and $5 and sold at $25 netting over 500% gain and bought my condo with proceeds)
Worst Call: Lpath (lost >80% after rec) ... a humbling reminder that my next call can always be a dud. This spurs me on to do the best DD that I can, while cutting losses and admitting my mistakes when wrong.
My work in the investment field spans over 30 years. I first became Series 7-licensed in 1980, and again in 2012 (now inactive), and have maintained a spotless regulatory compliance history throughout my career. I am a retired CPA and hold an accounting degree from Babson and Harvard MBA, along with CFA (Chartered Financial Analyst), and CFP (Certified Financial Planner) designations.
Data Driven Investing, a book I co-authored in 2004, may be viewed through Google Books at http://bit.ly/11uTzq6 . The book fully documents (with Fidelity statement excerpts) the 788% returns earned between 7/00 and 3/04 in my highly diversified, small cap value stock portfolio. Note that past performance does not guarantee future results.
In fact, my returns since 2004 have been significantly lower and are unlikely to ever approach 2000-2004 levels, due to my adoption of a more conservative style and the unusually high returns of small cap value from 7/00-3/04. As of 6/25/2016, my compounded annual returns for the past 16 years were 23.5% (including gains of 24.0% since 6/30/15). My recent returns have been boosted by synergies between crowdsourced research (i.e. Seeking Alpha) and the quantitative algorithms I've developed.
I'm currently the CEO of a business that will be publishing stock ratings based upon the strategies I use to manage my own money, and I intend to publish updated documentation of my returns as soon as permission to do so is received from the brokerages involved.
Peter Way Associates is the only known provider of the price range forecasts of widely-held, actively traded stocks derived from the hedging activities of market-making [MM] firms as they balance big-$-fund sellers and buyers in large block trades. The price ranges offer explicit downside exposure forecasts not commonly found in publicly published investment analyses.
This is all forward-looking data, based on what the MMs will pay for protection against coming unwanted price change while temporarily committed firm capital is exposed to market risks. It is available by modest subscription cost at blockdesk.com.
The behavioral analysis involved has been performed daily since Y2K, now on over 3,000 stocks, ETFs, and market indexes. That has built an actuarial history of how market prices have subsequently behaved following several million price range forecasts, issue by issue.
That data provides a qualitative backdrop to current forecasts in terms of odds of profitable positions, size of prospective gains, credibility of forecasts, and worst-case price drawdown exposure experiences.
Peter F. Way is a veteran Chartered Financial Analyst, having taken and passed the CFA Institute’s required 3 examinations in the first years they were given, 40+ years ago.
Armed with BS in Economics from the Wharton School and an MBA degree from Harvard Business School, he has managed staffs of dozens of Investment Researchers and Quantitative Analysts for the nation’s largest bank, arbitraged index options for NYSE Specialists, and managed portfolios of hundred-million-dollar equity investments for Fortune 100 corporate pension funds and non-profit endowments.
He has been elected President of professional Investment Analyst Societies in San Diego and New York City and has served on the editorial boards of the Financial Analysts Journal and the CFA Digest. He has spoken at numerous schools and professional meetings.
Netwall Investments, LLC (www.netwall.com) is a Chicago based money management firm. Our philosophy is derived from that of many legendary investors such as Warren Buffett, Peter Lynch & Martin Whitman; i.e. Invest in great businesses that you understand, that have an "economic moat" and which are run by great management teams; have some margin of safety and superior returns are guaranteed in the long run. These are the Ten rules that we religiously follow to manage other people's money:
1. I shall not lose money
2. I shall never forget rule #1
3. I shall only invest in businesses whose people I respect and admire
4. I shall only invest in businesses with some definite form of competitive advantage
5. I shall only invest when odds of making money are in my favor
6. I shall only commit funds when an investment is available at a discount to its true intrinsic value
7. I shall always run a portfolio with an in-depth understanding of each investment, thus avoiding mindless diversification
8. I shall always make rational decisions and never be influenced by the behavior of markets. I shall adhere to mantra, “Ignore the Crowd”
9. I shall tend to be fearful when others are greedy and be greedy when others are fearful (backed by meticulous research and fact finding)
10. I shall never forget that I am a custodian of other people’s hard earned money and I promise to manage it with the same zeal as if it were my own
I participate in Angel Investing and Venture Capital transactions. I have four years of experience in the Capital Markets. This includes, as a Qualified Investor, Angel Investing, Private Equity, Portfolio Management and Equity Trading. I achieved a Bachelors Degree in Business Finance at the University of Northern Colorado.
My preferred method of contact is via email at: firstname.lastname@example.org
I worked almost 30 years in the pharmaceutical industry. I started as a sales rep after earning my degree in biological sciences and (later) biomedical sciences. I then went back to school, got my MBA, and spent the following 20 years working up the ranks. I spent the latter parts of my career working as an analyst, meaning I would analyze data on 1,000s of compounds, collect reports from scientists, and then present the information to those who decided whether the candidates would go on to clinical trials (additional preclinical studies) or would be thrown to the dumpster for some small company to find and develop further. I have worked in just about every department in the pharmaceutical industry, including biotechnology, oncology, infectious disease, genetics, etc.
Now that I am recently retired, I have joined Seeking Alpha to share my knowledge of the healthcare industry, and discuss trends that I've seen throughout my career. I have chosen the task of managing my own retirement accounts, therefore Seeking Alpha has become a great interest to me.
I am hoping to learn and teach via Seeking Alpha. Also, my grandchildren call me Shennie so that's what I go by these days
Long time biotech and tech investor who enjoys discussing stocks, options, and sharing ideas freely.
Investors buy or sell at their own risk. All my articles strictly represent an 'opinion' and in no-way should be construed as individual investor advice.
The Clinically Sound Investor is a pharmacist for a large retail corporation, with a PharmD and a BA in psychology. Fascinated by watching the rise of Walmart and Apple after 2008, he now follows the advice "know thyself" and puts expertise of understaning scientific literature to research biotechnology stocks. His investments early on were driven by binary events such as FDA Advisory Committee meetings and PDUFA dates (approvals). Despite initial successes, there were too few of these events, so he expanded into predicting Phase II/III trial results.
His writings should not be considered financial advice or the basis for investment decisions. While his interpretations of clinical trial results--which may be overlooked or even thoroughly misunderstood by Wall Street--could be helpful, they're only as good as the original reports they come from. Although written by scientists and doctors, there will always be a slant from the sponsoring company, or worse (like, say, missing data...).
(Note: updates to my SA articles & some original articles may appear in my blog. So check it (below) from time to time.)
I am a retired broker from TD Ameritrade (series 7,63,24 & 4)as of January 1st (2010). However, I have worked in general management in manufacturing and business logistics as well as railroading for a number of Fortune 500 companies. My earliest post college experiences included 2 years in the US Army (Staff Sergeant) in the 1st Infantry Division in South Vietnam. My degree is in Economics from the University of Maryland and I hold an MBA as well. My current activities, besides day trading include projects associated with the Texas Master Naturalist and the Texas Bluebird Society - 2013 Texas Bluebirder of The Year, getting back into shape (recently hit my goal after losing 35 lbs), jogging, swimming, resistance training and following the exploits of my children and grandchildren.
“The way to win is to work, work, work, work and hope to have a few insights.”
– Charlie Munger
“People err who think my art comes easily to me. I assure you, dear friend, nobody has devoted so much time and thought to compositions as I. There is not a famous master whose music I have not industriously studied through many times.”
- Wolfgang Amadeus Mozart
"It is better to be roughly right than precisely wrong."
- John Maynard Keynes
My time frame for looking at an investment would generally be between two to five years.
Individual investor focused upon a limited number of diversified stocks. Seeks stocks selling below fair value; favors dividend growth. Advocates fundamental investment analysis, supplemented by the technical charts. Options strategies primarily employed to generate additional income or hedge risk.
Ms. Williams is a Certified Public Accountant whose writing will focus on analyzing financial statements and their implications for investors. She holds an MBA from the University of Miami and a BA from the University of Virginia.
Chief Market Strategist at www.buysellshort.net. Learn how to make a living trading small and midcap stocks
Additional Disclaimer: I may buy and sell any positions mentioned in any article at any time.
Former sell-side media, consumer and internet research analyst for 15 years.
Why the pseudonym Lord Baltimore? He was a famous native american scout in the late 1800's as well as an intense character in Butch Cassidy and The Sundance Kid who relentlessly tracked the two heroes. (A 1970s heavy metal band was similarly inspired by the film character in selecting its name.) I view investing a lot like tracking. It is a process of putting together clues found along a trail to determine the path of the target, which in this case is attractive investments - long or short.
Contributors: Scott Tzu, Parke Shall, Thom Lachenmann
(contributors write under pen names for anonymity purposes)
Please read Seeking Alpha's Policy on Anonymous Contributors to familiarize yourself with the site's terms and conditions relating to anonymous authors.
PhaseFive initiates research-intensive analysis of Healthcare and Biotechnology companies using groundbreaking scientific intelligence tools. We focus on long/short event-driven opportunities centered on clinical, regulatory and early commercial development.
Our research approach relies on synergizing diverse talents. PhaseFive’s team is built on the knowledge and vast experience of Neurobiochemistry PhDs, Big Data experts and seasoned Life Science investors. Our track record reflects our ability to assess a company’s true fair value at critical stages, looking beyond hype and misunderstood perceptions.
PhaseFive focuses on catalyst events in small-to-medium cap Healthcare companies. These catalyst events include clinical trial outcomes, regulatory procedures and commercial developments.
Mark Krieger is an avid stock market trader dedicated to the following ideals: (1) Focus on high relative strength, (2) Buy low, sell high (3) Short high, cover low, (4) Go against the crowd, (5) It's all about the rules and discipline- hold them dear (6) Analyze the balance sheet-seek low debt,high cash and hidden value scenarios (7) Cut your losses short, let your gains run, (7) Don’t get emotional, (8) Follow the insiders- buy if they are buying, sell if they are selling (9) Be greedy when others are fearful and fearful when others are greedy.(10) Don't argue with the market unless you detect an inefficiency present-it is smarter than you are. In summary, some of these ideas might be construed as rather trite and overused, but consistent use of them pays off in the long run.
Mr. Krieger specializes in the food sector and is the originator of the "Basic Food Fund" index and the "Dirt Cheap Value Portfolio".Why the food sector? "everybody has to eat'!
He graduated from the University of Southern California with a BS in Business Administration with an emphasis in Corporate Finance. Mark resides in Cowan Heights, California with his wife, son and pug and is interested in mountain biking, gardening and reading.
Hedge Fund Insights is a premium service tailored to long-term oriented value investors. We provide subscribers with detailed idea analysis, real-time trade updates, and portfolio composition.
"It's like having your own hedge fund analyst."
Our TipRank profile: https://www.tipranks.com/bloggers/hfi
The professionals at Eight Diamonds Advisors have on average more than 20 years of experience working in the financial markets. Their backgrounds cover a broad swath of disciplines including M&A, restructuring, forensic accounting, investment management and research analysis.
I am an Senior Biotech Analyst with Zacks Investment Research, Inc. I joined Zacks in February 2014.
Prior to joining Zacks, I was an NRSA Postdoctoral Fellow working in a cancer genetics laboratory.
I received my PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill. I also have my BS and MS in Biochemistry from Virginia Tech.
I have spent 7 years investing. Seven years isn't a long time but I have acquired an enormous amount of experience. My 7 years of experience has resulted in a deeper understanding of the investment process and financial markets. I focus on a company's business model, industry positioning and valuation. These factors help discover companies built for long term success. Investing requires constantly learning and acquiring new skills. As a result, I am pursuing the Chartered Financial Analyst designation.
I am a senior at Queens College studying Pre-Med/Biochemistry. I also have a passion for investing and the stock market, and have been observing the stock market and actively investing for over three years now. While I will at times look at stocks from all sectors and industries I tend to focus on biotech and pharmaceuticals.
I have been trading part time for the past 10 years, focusing on swing trades and identifying how different stocks will "inhale and exhale" through the market. My primary targets are in the $2-$10 range, averaging over 2 million shares traded daily, and looking for an upswing. My goal is to average 10% per month, but will hold on for the long run with stocks that I believe in.
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a Technology Transfer Officer at UCLA. He has a B.S. from Penn State University and an MBA from Rutgers University.
His WEB site at www.raygent.com is currently focused in biopharmaceuticals, genomics and clinical diagnostics . Mr. Raynovich has extensive expertise in marketing and product development and provides business development consulting to early stage companies in biotechnology, diagnostics and imaging.
The Rayno Life Science Portfolio was published on www.raygent.com and other trade media.
Articles have been published on the following topics: Alzheimer Disease,Biomarkers, Genomics,Molecular Diagnostics, Oncology Drugs, Personalized Medicine, Targeted Therapy, Technology Trends, H1N1 and Government Policy on biotechnology.
The Life Science Portfolio is up over 80% over a 24 mo. period as of 5/30/14and among the life science portfolio winners are ABAX, ALXN, AMRI, BIIB, CBST, GPRO, ILMN, QDEL,REGN, SGEN, and VPHM.